Fed raises rates 0.25% amid banking crisis, signals hikes nearing end

Sangamo Therapeutics, Inc. (SGMO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Visitors trend2W10W9M

1.8396

-0.0604

(-3.18%)

As of 02:39PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	1.9000
Open	1.9200
Bid	1.8400 x 1300
Ask	1.8500 x 4000
Day's Range	1.8200 - 1.9250
52 Week Range	1.8200 - 6.4200
Volume	895,592
Avg. Volume	1,608,867

Market Cap	354.864M
Beta (5Y Monthly)	1.17
PE Ratio (TTM)	N/A
EPS (TTM)	-1.1800
Earnings Date	May 03, 2023 - May 08, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	11.24

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SGMO

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Sangamo Therapeutics, Inc.
Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
Rating
Fair Value
Economic Moat
7 days agoArgus Research

All

Zacks
Sangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Invesco Mortgage Capital (IVR) Loses -20.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
  Zacks
- Down -23.37% in 4 Weeks, Here's Why Heartland Financial (HTLF) Looks Ripe for a Turnaround
  Zacks
Benzinga
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategi
Zacks
Sangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sangamo (SGMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Sangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
  Zacks
- After Plunging -21.91% in 4 Weeks, Here's Why the Trend Might Reverse for Alexandria Real Estate Equities (ARE)
  Zacks